Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823740 | 1.00 | MAPK8 (0.46) | MAPK8MAPK9IRAK4NTRK1FLT3 | |
| SCHEMBL3612465 | 0.95 | IRAK4 (0.48) | MAPK8MAPK9IRAK4NTRK1FLT3 | |
| SCHEMBL3607933 | 0.86 | HDAC3 (0.39) | MAPK8MAPK9IRAK4NTRK1FLT3 | |
| SCHEMBL3612994 | 0.82 | GRM4 (0.47) | GRM5GRM4 | |
| SCHEMBL823779 | 0.78 | LRRK2 (0.38) | MAPK8MAPK9IRAK4NTRK1FLT3 | |
| SCHEMBL825987 | 0.78 | LRRK2 (0.38) | MAPK8MAPK9IRAK4NTRK1FLT3 | |
| SCHEMBL3617502 | 0.76 | TSHR (0.44) | GRM5GRM4ACACB | |
| SCHEMBL3609937 | 0.75 | ACACB (0.43) | IRAK4GRM5GRM4ACACB | |
| SCHEMBL823611 | 0.75 | RORC (0.39) | MAPK8MAPK9 | |
| SCHEMBL4119354 | 0.75 | MAPK8 (0.40) | MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | MAPK8 3434/4885MAPK9 3997/4885IRAK4 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.